Recombinant factor VIIa use in patients with the rarest forms of inherited coagulation-factor deficiencies: a study of cases from the www.haemostasis.com registry
Tóm tắt
Rare inherited coagulation disorders (RICDs) with a prevalence of ≤1/1,000,000 include deficiencies in factor II, factor V, combined factor V/factor VIII, factor X, factor XI and factor XIII. These abnormalities are associated with spontaneous haemorrhage and excessive bleeding after surgery or trauma. Management is complicated by limited information and variations in biochemical characteristics and bleeding phenotypes. The independently managed international registry,
http://www.haemostasis.com
, was established to collect data on investigational use of activated recombinant factor VII (rFVIIa) in preventing or treating severe bleeding episodes. Patients suffering from the rarest forms of RICDs and receiving rFVIIa as treatment were identified from the
http://www.haemostasis.com
registry. Case providers were contacted to verify data and obtain consent for inclusion in this study. Eleven patients were identified; permission for inclusion was declined in two cases. The nine cases reported in this study included patients with factor II, factor V, combined factor V/factor VIII, combined factor V/von Willebrand’s disease, factor X, factor XI, factor XI with inhibitors and factor XIII deficiencies. The median individual dose of rFVIIa was 105.9 μg/kg body weight (range: 55–508 μg/kg), whereas the median total dose was 327.3 μg/kg body weight (range: 78.4–880 μg/kg). rFVIIa treatment was associated with a decrease, cessation or prevention of bleeding in eight cases; bleeding after trauma remained unchanged in one case of factor XIII deficiency. Positive pro-coagulatory responses were shown to occur at a wide range of anatomical sites. No deaths or rFVIIa-related adverse events were reported. In conclusion, this study suggests that rFVIIa has a favourable safety profile and that it may be used to treat or prevent haemorrhage in patients with RICDs.
Tài liệu tham khảo
Abshire T, Kenet G (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2:899–909
Allen GA, Monroe DM, Roberts HR et al (2000) The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis 11(Suppl 1):S3–S7
Anonymous (2005) Summary product characteristics for NovoSeven for Europe. http://www.emea.eu.int
Bauer KA (1996) Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis 26(Suppl 1):155–158
Berrettini M, Mariani G, Schiavoni M et al (2001) Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 86:640–645
Board PG, Losowsky MS, Miloszewski KJ (1993) Factor XIII: inherited and acquired deficiency. Blood Rev 7:229–242
Boggio L, Green D (2001) Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol 112:1074–1075
Bolton-Maggs PH, Young Wan-Yin B, McCraw AH (1988) Inheritance and bleeding in factor XI deficiency. Br J Haematol 69:521–528
Bolton-Maggs PH, Patterson DA, Wensley RT et al (1995) Definition of the bleeding tendency in factor XI-deficient kindreds—a clinical and laboratory study. Thromb Haemost 73:194–202
Bolton-Maggs PH, Perry DJ, Chalmers EA et al (2004) The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 10:593–628
Divanon F, Hecquard C, Borel-Derlon A (2002) Experience with use of recombinant activated factor VII. J Clin Pharm Ther 27:133–138
Hoffman M, Monroe DM (2001) A cell-based model of hemostasis. Thromb Haemost 85:958–965
Jurlander B, Thim L, Klausen NK et al (2001) Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 27:373–384
Kessler C (2004) Haemostasis.com: clinical experiences in the investigational use of rFVIIa in the management of severe haemorrhage. Br J Haematol 127:230
Lawler P, White B, Pye S et al (2002) Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 8:145–148
Mannucci PM, Duga S, Peyvandi F (2004) Recessively inherited coagulation disorders. Blood 104:1243–1252
Monroe DM, Roberts HR (2003) Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol 23:8–9
O’Connell NM (2004) Factor XI deficiency. Semin Hematol 41:76–81
O’Connell KA, Wood JJ, Wise RP (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295:293–298
Ozelo MC, Svirin P, Larina L (2005) Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard–Soulier syndrome. Ann Hematol 84:816–822
Peyvandi F, Mannucci PM (1999) Rare coagulation disorders. Thromb Haemost 82:1207–1214
Peyvandi F, Duga S, Akhavan S (2002) Rare coagulation deficiencies. Haemophilia 8:308–321
Tuddenham EGD, Cooper DN (1994) The molecular genetics of haemostasis and its inherited disorders, 25th edn. Oxford Medical Publications, Oxford, UK